Benfotiamine Research
38 peer-reviewed studies · Evidence score: 8.5/10
Vitamin B and its derivatives for diabetic kidney disease
Raval AD et al. • The Cochrane database of systematic reviews (2015)
There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
- There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
- Thiamine was found to be beneficial for reduction in albuminuria in a single study; however, there was lack of any improvement in kidney function or blood pressure following the use of vitamin B preparations used alone or in combination.
- These findings require further confirmation given the limitations of the small number and poor quality of the available studies.
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Muley A et al. • BMJ open (2022)
Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was not demonstrated in higher doses.
- There was a significant increase in high-density lipoprotein (HDL) (MD, 0.10; 95% CI: 0.10 to 0.20) at 3-month follow-up.
- Benfotiamine reduced triglyceride level (MD, -1.10; 95% CI: -1.90 to -0.30) in 120 mg/day dose as compared with placebo 150 mg/day, however this was not demonstrated in higher doses.
- Further research warranted to confirm findings
Pathogenetic treatments for diabetic peripheral neuropathy
Ziegler D • Diabetes research and clinical practice (2023)
Published by Elsevier B.V.
- The NATHAN 1 trial demonstrated an improvement of neuropathic signs (deficits, impairments) after four years in asymptomatic DPN.
- These compounds are currently authorized for treatment of DPN in several countries.
- Long-term pivotal clinical trials should further establish their value as mono- and combination therapies in DPN.Copyright © 2023.
Novel Therapies for Kidney Disease in People With Diabetes
Khurana N et al. • The Journal of clinical endocrinology and metabolism (2022)
Trials have yielded promising results in the search for new therapies to manage DKD.
- Trials have yielded promising results in the search for new therapies to manage DKD.
- SGLT2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes.
- Mineralocorticoid receptor antagonists are another class of agents with increasing evidence of benefits.
Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations
Ziegler D et al. • Diabetes research and clinical practice (2022)
All rights reserved.
- Painful DSPN is encountered in 13-26% of diabetes patients, while up to 50% of patients with DSPN may be asymptomatic.
- Considering the individual risk profile, pain management should not only aim at pain relief, but also allow for improvement in quality of sleep, functionality, and general quality of life.Copyright © 2021 The Authors.
- Published by Elsevier B.V.
Therapeutic potential of vitamin B(1) derivative benfotiamine from diabetes to COVID-19
Allowitz KV et al. • Future medicinal chemistry (2022)
In this review article, the authors discuss the significance of benfotiamine in the prevention of various pathological complications.
- In addition to potent antioxidative properties, benfotiamine has also been shown to be a strong anti-inflammatory agent with therapeutic significance to several pathological complications.
- Specifically, over the past decade or so, benfotiamine has been shown to prevent not only various secondary diabetic complications but also several inflammatory complications such as uveitis and endotoxemia.
- Recent studies also demonstrate that this compound could be used to prevent the symptoms associated with various infectious diseases such as HIV and COVID-19.
[On the specific treatment of asthenic states: focus on sulbutiamine]
Bykov YV et al. • Terapevticheskii arkhiv (2022)
Our results also show that Enerion has some clinically relevant advantages over all alternatives we reviewed there.
- Then we analyze and summarize the available evidence base considering the efficacy and safety of Enerion for the treatment of asthenic syndromes.
- Then we compare Enerion with some other drugs.
- The results of our review indicate the high efficacy and safety of sulbutiamine in the treatment of asthenia.
Current concepts in the management of diabetic polyneuropathy
Ziegler D et al. • Journal of diabetes investigation (2021)
Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.
- Painful DSPN might be as frequent as 25% in diabetes patients.
- Asymptomatic DSPN might reach 50% among patients with this condition.
- Symptomatic therapy uses analgesics, notably antidepressants, opioids and anticonvulsants, reducing pain by ≥50% in approximately 50% of individuals, but might be limited, particularly by central nervous system-related adverse events.
Therapeutic potential of benfotiamine and its molecular targets
Raj V et al. • European review for medical and pharmacological sciences (2018)
In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects.
- The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes.
- The effects of BFT on the AGE-dependent pathway is well established.
- In the present review, we have comprehensively reviewed all the molecular targets modulated by BFT to provide mechanistic perspective to highlight its pleiotropic effects.
Inflammatory Activities in Type 2 Diabetes Patients With Co-morbid Angiopathies and Exploring Beneficial Interventions: A Systematic Review
Nwadiugwu MC • Frontiers in public health (2020)
Conclusion: Inflammatory activities are implicated in diabetes-related angiopathies; regular exercise, the intake of healthy dietary supplements, and medications with anti-inflammatory properties could result in improved protective risk outcome for diabetes patients by suppressing inflammatory activities and elevating anti-inflammatory events.Copyright © 2021 Nwadiugwu.
- Use of drugs such as salsalate, pioglitazone, simvastatin, and fenofibrate but not glimepiride or benfotiamine reported a significant decrease in inflammatory events.
- Results: Data analysis showed that elevated CRP, TNF-α, and IL-6 were the most commonly found inflammatory indicator in diabetes-related angiopathies, while increased IL-10 and soluble RAGE was an indicator for better outcome.
- Regular exercise and consumption of dietary supplements such as ginger, hesperidin which have anti-inflammatory properties, and those containing prebiotic fibers (e.g., raspberries) revealed a consistent significant (p < 0.05) reduction in inflammatory activities.
Advances in the management of diabetic neuropathy
Várkonyi T et al. • Minerva medica (2017)
The authors conclude that combination therapy should be more often suggested to our patients; especially the combination of pathogenetic and symptomatic agents.
- Beyond additional forms of causal treatment, choices of symptomatic treatment will be summarized.
- The latter is mostly represented by the anticonvulsive agents pregabalin and gabapentin as well as duloxetine widely acknowledged as antidepressant.
- Finally, non-pharmacological therapeutic alternatives are summarized.
Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update
Bhattacharjee N et al. • European journal of pharmacology (2016)
All rights reserved.
- Beside this, some therapeutic agents are still waiting for FDA approval and few drugs without FDA approval are also prescribed in some countries for the management of DN.
- Despite the medications available in the market to treat DN, the involvement of multiple mechanisms makes it difficult to choose an optimum therapeutic agent.
- Therefore, much research is required to find out new therapeutic agent/strategies for an adequate pharmacotherapy of DN.Copyright © 2016 Elsevier B.V.
Vitamin B for treating peripheral neuropathy
Ang CD et al. • The Cochrane database of systematic reviews (2008)
There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful.
- There are only limited data in randomised trials testing the efficacy of vitamin B for treating peripheral neuropathy and the evidence is insufficient to determine whether vitamin B is beneficial or harmful.
- One small trial in alcoholic peripheral neuropathy reported slightly greater improvement in vibration perception threshold with oral benfotiamine for eight weeks than placebo.
- In another small study, a higher dose of oral vitamin B complex for four weeks was more efficacious than a lower dose in reducing symptoms and signs.
Drugs for the treatment of diabetes complications. Zycose: a new player in the field?
Stirban A • Drugs of today (Barcelona, Spain : 1998) (2008)
All rights reserved.
- The complex composition of Zycose allows the therapeutic intervention of several hyperglycemiamediated disorders.
- The compound consists mainly of vitamins, therefore explaining, in part, the good safety profile and reduced adverse effects.Copyright 2008 Prous Science, S.A.U. or its licensors.
- All rights reserved.
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy
Bönhof GJ et al. • BMJ open (2022)
This rct examined the effects of Benfotiamine.
- Clinical trial examining Benfotiamine efficacy
- Published in BMJ open (2022)
- Further research warranted to confirm findings
A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes
Stirban A et al. • Diabetic medicine : a journal of the British Diabetic Association (2013)
In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function.
- Participants had an impaired baseline flow-mediated dilatation (2.63 ± 2.49%).
- In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function.
- Further research warranted to confirm findings
Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study
Garg S et al. • The Clinical journal of pain (2013)
Net change in serum nitrite, -0.15±0.01 versus -0.79±0.12 µmol/L, P<0.001; AGEs, -0.12±0.02 versus -0.99±0.09, arbitrary florescence units, P=0.001; thiobarbituric acid reactive substances, -0.69±0.12 versus -1.80±0.12 nmol/L, P<0.01; C-reactive protein, -0.12±0.35 versus -2.45±0.60 mg/L, P<0.01, were observed in the placebo versus drug group, respectively.
- Clinical trial examining Benfotiamine efficacy
- Published in The Clinical journal of pain (2013)
- Further research warranted to confirm findings
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial
Fraser DA et al. • Diabetes care (2012)
Our findings suggest that high-dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.
- Our findings suggest that high-dose benfotiamine (300 mg/day) supplementation over 24 months has no significant effects upon peripheral nerve function or soluble markers of inflammation in patients with type 1 diabetes.
- Published in Diabetes care (2012)
- Further research warranted to confirm findings
Pain Bloc-R Alleviates Unresolved, Non-Pathological Aches and Discomfort in Healthy Adults-A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
Evans M et al. • Nutrients (2020)
Pain Bloc-R performed as well as acetaminophen in managing unresolved non-pathological pain in otherwise healthy individuals.
- The BPI "pain at its worst" scores were significantly lower when participants took Pain Bloc-R than when they took acetaminophen (21.8% vs. 9.8% decrease, p = 0.026) after seven days of supplementation.
- Pain Bloc-R achieved a significant improvement in the "pain at its least" score, significantly decreased the interference of discomfort in walking, and significantly decreased musculoskeletal discomfort total scores (34%, p = 0.040) after seven days.
- In a post hoc subgroup analysis based on age and gender, male participants ≤45 years taking Pain Bloc-R reported significant reductions in pain severity and pain interference vs. acetaminophen.
Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months
Stirban OA et al. • Journal of diabetes and its complications (2020)
This rct examined the effects of Benfotiamine.
- Clinical trial examining Benfotiamine efficacy
- Published in Journal of diabetes and its complications (2020)
- Further research warranted to confirm findings